Could your subconscious mind affect your Parkinson’s treatment outcomes?
PD in Practice
sponsored by UCB
Author: UCBPublished: 15 February 2018
Prep: Cook: Serves:
By using innovative research, people living with Parkinson’s, caregivers and healthcare professionals have shed new light into the subconscious and behavioural influences that affect decision-making around treatment for the condition
When an individual is diagnosed with Parkinson’s, many factors can influence their behaviour, the way they make decisions, and the actions they take to manage their condition. Our own individual biases and perceptions can shape, change or reinforce beliefs related to treatment. In the case of Parkinson’s, people are grappling with a condition with an uncertain outcome and a range of treatments to choose from.
To understand these subconscious influences on treatment behaviour, an innovative behavioural market research (“research”) programme, called DRIVE™, was conducted with people with Parkinson’s, carers and healthcare professionals following these main principles:
The programme looked at how people with Parkinson’s:
evaluate various moments in their treatment journey
set their goals and expectations from treatment
cope with various challenges
understand the roles and inputs of others
evaluate the effectiveness, tolerability and cost-benefit of medication – and what impact this has on their adherence to treatment.
“Parkinson’s disease is a very individual experience”
The key findings of the DRIVE™ programme were:
1. From subjectivity to objectivity People with Parkinson’s are often primed with experiences and information that leaves them feeling uncertain about how things will progress and how different treatments might affect them. Finding ways to more objectively measure wellbeing, tolerability and treatment goals related to efficacy may help people make a more positive assessment of these factors.
2. Openness to treatment trials varies People with Parkinson’s are more likely to be open to trying something different. Psychologically, they are generally primed for loss, and, in this situation, may be more willing to take a decision even if the gain is uncertain – adopting a mindset of ‘I have nothing to lose’. On the other hand, some individuals will hold onto a minimal gain for fear of a greater loss – perhaps being afraid to change from a sub-optimal treatment in case an alternative would be even less effective, or could introduce additional or intolerable side-effects. In this instance, a patient would be less open to change.
3. Roles evolve over time As Parkinson’s progresses, control over treatment choices also evolves. Initial decisions over treatment may be driven by healthcare professionals, primarily based on medication efficacy. But over time, the balance switches to people living with Parkinson’s, some of whom will build a picture of what works for them, and will need to share this with others to optimise their treatment.
Providing appropriate information at each phase should aid decision making and optimise treatment choice. Decisions about switching treatment – which involves weighing up the desirable and undesirable aspects of existing treatments against the unknown risks of an alternative – will be motivated, at least to some degree, by subconscious influences.
Personalisation is key
Parkinson’s disease is a very individual experience. By recognising this, and identifying the factors which motivate individuals in their decisions about treatment – instead of using the more standard guidelines such as disease stage or symptoms tracking – we may be able to approach such decisions on a more personal basis. More should be done to reduce the uncertainty that patients face at the start of treatment, and while evaluating treatments as their disease progresses. Preparing people with Parkinson’s for their experience could optimise their treatment and improve their overall quality of life. Ref: HQ/1217/NU/00087
About UCB UCB is a global biopharmaceutical company with a focus on neurology.
UCB is committed to identifying and addressing the unmet needs of people living with Parkinson’s disease to enable them to have a more engaged life every day.
This research was conducted by Final Mile Consulting on behalf of UCB.
The authors thank the people living with Parkinson’s, and all other participants in addition to the researchers and their teams who contributed to this research.
DRIVE™ is a trademark of UCB Biopharma SPRL.
To get access to the full report, please go on UCB.com.
This article is sponsored by UCB. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Salmon fishcakes with chilli and mayo red dressing
These fishcake gems are rich in omega-3 and so easy to prepare
5 hours ago
Study suggests why neurons die in Parkinson’s disease
Researchers at the University of Córdoba, Spain, have discovered how a certain protein may be linked to death of dopamine-producing neurons associated with Parkinson’s. Using animal models of the condition to conduct their study, the team focused on the protein DJ-1 – whose link to Parkinson’s has previously been established, though its exact function was uncertain. The researchers compared neurons in the brains of mice that possessed the gene expressing DJ-1 with those that did not. The findings revealed that dysfunction or absence of the gene expressing the DJ-1 protein could trigger the ‘cell cycle’ (the process by which cells divide), which should not occur under normal conditions. Because neurons lack the capacity to divide, this causes them die – leading to the onset of symptoms linked with Parkinson’s. It is hoped that uncovering these details about the relationship between DJ-1’s absence and Parkinson’s may lead to the development of…
Researchers have finally identified brain cells linked to Parkinson’s disease
For decades, scientists have known that Parkinson’s is associated with the death of dopamine-producing cells in the brain. Now, researchers from the Broad Institute of MIT and Harvard, US, have discovered the specific subtype of brain cells that die in Parkinson’s disease. Using a technique called single-cell RNA signalling, which enables the individual analysis of cells within a tissue for activity and protein production, researchers identified 10 subtypes of dopamine-producing cells within the donated brains of people who died from causes unrelated to Parkinson’s. The team carried out the same investigation on people who had died with Parkinson’s or a condition with similar symptoms called Lewy body dementia. They discovered that only one subtype of the cells had reduced in number – which suggests many of these cells had died while the people were living. It is hoped that the findings could lead to better understanding of Parkinson’s causes and…
Tiny DBS implant shows potential to advance Parkinson’s disease treatment
In an innovative trial by North Bristol NHS Trust, UK, surgeons have succeeded in implanting a tiny deep brain stimulation (DBS) device into a person’s skull. Their aim? To address symptoms of Parkinson’s. Designed with a tiny battery system that is inserted into the skull, the DBS device delivers electric impulses to targeted areas of the brain through electric probes. In doing so, it works to address abnormal brain cell activity associated with Parkinson’s – and may help to ease symptoms. One of around 25 patients selected for the year-long trial has described the device’s impact as “amazing”. Commenting on the results of the trial so far, consultant neurologist Dr Alan Whone of North Bristol NHS Trust said: “We are hopeful that if these findings hold up, we will have a significant technical advance by which to improve Parkinson’s care across the world.”